Blastic plasmacytoid dendritic cell neoplasm: Clinical features in 90 patients

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 579-586

  Julia, F ^a   Petrella, T ^b,c   Beylot Barry, M ^c,d   Bagot, M ^c,e   Lipsker, D ^c,f   Machet, L ^c,g   Joly, P ^c,h   Dereure, O ^c,i   Wetterwald, M ^c,j   D'Incan, M ^c,k   Grange, F ^c,k,l   Cornillon, J ^m   Tertian, G ⁿ   Maubec, E ^c,n   Saiag, P ^c,o   Barete, S ^c,p   Templier, I ^c,q   Aubin, F ^a,r   Dalle, S ^a,c  

^a HOSPICES CIVILS DE LYON   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c French Study Group on Cutaneous Lymphoma (GFELC)   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITÉ DE STRASBOURG   (France)

^g UNIVERSITÉ DE TOURS   (France)

^h UNIVERSITÉ DE ROUEN   (France)

ⁱ UNIV MONTPELLIER   (France)

^j General Hospital   (France)

^k UNIVERSITÉ CLERMONT AUVERGNE   (France)

^l SERVICE DE DERMATOLOGIE   (France)

^m Institut de Cancerologie de la Loire   (France)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^o LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^p HÔPITAL TENON   (France)

^q Lyon Universitary Hospital   (France)

^r UNIVERSITÉ DE FRANCHE COMTÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL CANCER; BONE MARROW BIOPSY; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; MYELOMA; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; RARE DISEASE; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN CANCER; SKIN DEFECT; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DELAYED DIAGNOSIS; DENDRITIC CELLS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84883441321     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12412     Document Type: Article

References (31)

1. Willemze R, Jaffe ES, Burg G, et al,. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
2. Swerdlow SH, Campo E, Harris NL, et al,. Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th edn. Geneva: World Health Organization, 2008; 1-441.
3. Petrella T, Facchetti F,. Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009? Autoimmunity 2010; 43: 210-14.
4. Chaperot L, Bendriss N, Manches O, et al,. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210-17.
5. Jegalian AG, Facchetti F, Jaffe ES,. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol 2009; 16: 392-404.
6. Petrella T, Comeau MR, Maynadié M, et al,. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852-62.
7. Reizis B, Bunin A, Ghosh HS, et al,. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 2011; 29: 163-83.
8. Marafioti T, Paterson JC, Ballabio E, et al,. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 2008; 111: 3778-92.
9. Cota C, Vale E, Viana I, et al,. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010; 34: 75-87.
10. Garnache-Ottou F, Feuillard J, Saas P,. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol 2007; 136: 539-48.
11. Jegalian AG, Buxbaum NP, Facchetti F, et al,. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica 2010; 95: 1873-9.
12. Yang CS, Wang J, Chang TK,. Congenital blastic plasmacytoid dendritic cell neoplasm. Pediatr Blood Cancer 2012; 58: 109-10.
13. Dalle S, Beylot-Barry M, Bagot M, et al,. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2010; 162: 74-9.
14. Reimer P, Rüdiger T, Kraemer D, et al,. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003; 32: 637-46.
15. Machet L, De Muret A, Wiezberka E, et al,. Agranular CD4+ CD56+ CD123+ hematodermic neoplasm (blastic NK-cell lymphoma) revealed by cutaneous localization: two cases [Article in French]. Ann Dermatol Venereol 2004; 131: 969-73.
16. Petrella T, Meijer CJ, Dalac S, et al,. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol 2004; 122: 307-13.
17. Tap WD, Gong KW, Dering J, et al,. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 2010; 12: 637-49.
18. Fontaine J, Thomas L, Balme B, et al,. Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment. Clin Exp Dermatol 2009; 34: e43-5.
19. Leitenberger JJ, Berthelot CN, Polder KD, et al,. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 2008; 58: 480-4.
20. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, et al,. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 2010; 34: 438-46.
21. Petrella T, Bagot M, Willemze R, et al,. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005; 123: 662-75.
22. Hashikawa K, Niino D, Yasumoto S, et al,. Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm. J Am Acad Dermatol 2012; 66: 278-91.
23. Feuillard J, Jacob MC, Valensi F, et al,. Clinical and biologic features of CD4+CD56+ malignancies. Blood 2002; 99: 1556-63.
24. Jacob MC, Chaperot L, Mossuz P, et al,. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 2003; 88: 941-55.
25. Rossi JG, Felice MS, Bernasconi AR, et al,. Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome. Leuk Lymphoma 2006; 47: 715-25.
26. Guo J, Si L, Kong Y, et al,. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-9.
27. Rauh MJ, Rahman F, Good D, et al,. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: case series and literature review. Leuk Res 2012; 36: 81-6.
28. Roos-Weil D, Dietrich S, Boumendil A, et al,. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2013; 121: 440-6.
29. Jaye DL, Geigerman CM, Herling M, et al,. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol 2006; 19: 1555-62.
30. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R,. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004; 15: 1097-108.
31. Lucioni M, Novara F, Fiandrino G, et al,. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood 2011; 118: 4591-4.